Peripheral blood TCR marker of acute B lymphocytic leukemia as well as detection kit and application of peripheral blood TCR marker

Abstract

The invention discloses a peripheral blood TCR marker of acute B lymphocytic leukemia as well as a detection kit and application of the peripheral blood TCR marker. The peripheral blood TCR marker comprises at least one of proteins of which the sequences are as shown in SEQ ID NO.1-100. On the basis of a high-throughput sequencing method, only a small amount of peripheral blood needs to be adopted, RNA is extracted, an immune map library is established by treating a sample, then through high-throughput sequencing and TCR data analysis, firstly, a characteristic TCR sequence in the peripheral blood of the acute B lymphocytic leukemia is determined, and then a test result of a to-be-tested sample is compared with the characteristic TCR sequence, therefore, whether a patient suffers from acute B lymphocytic leukemia is determined. According to the peripheral blood TCR marker, a huge number of acute B lymphocytic leukemia specific TCR sequences can be compared at the same time, and the peripheral blood TCR marker has higher specificity, higher accuracy and improved diagnosis efficiency compared with single detection of one or more markers.

Description

technical field [0001] The invention belongs to the technical field of genetic engineering, and in particular relates to a peripheral blood TCR marker of acute B lymphocytic leukemia, a detection kit and application thereof. Background technique [0002] Acute Lymphoblastic Leukemia (ALL) is a malignant tumor disease originating from the abnormal proliferation of B-lineage or T-lineage lymphoid progenitor cells in the bone marrow. Abnormally proliferating blast cells can gather in the bone marrow and inhibit normal hematopoietic function, and can also invade tissues outside the bone marrow, such as meninges, lymph nodes, gonads, and liver. my country has conducted a survey on the incidence of leukemia, and the incidence of ALL is about 0.67 / 100,000. The incidence rate in oil fields and polluted areas is significantly higher than the national incidence rate. ALL childhood (0 to 9 years old) is the peak incidence, which can account for more than 70% of childhood leukemia. A...

AI Technical Summary

Problems solved by technology

This type of detection has a fast measurement speed and can measure multiple parameters, but its sensitivity is not enough, and antigenic drift may occur in patients with minimal residual disease in ALL patients, resulting in false negative results of flow cytometry

[0007] PCR includes real-time fluorescent quantitative RCR (qPCR) and reverse transcription PCR (RT-PCR), both of which have high sensitivity for detecting minimal residual disease, but the results are prone to false negatives

Images